{"analyses":[{"ciLowerLimit":"0.70","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.98","estimateComment":"Stratified Cox Proportional Hazards model. A hazard ratio \\< 1 favours Dato-DXd.","groupDescription":"Dato-DXd versus ICC","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.83"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.4","upperLimit":"15.0","value":"13.7"},{"groupId":"OG001","lowerLimit":"10.8","upperLimit":"13.7","value":"12.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"365"},{"groupId":"OG001","value":"367"}],"units":"Participants"}],"description":"Time to second subsequent therapy is defined as the time from randomization to until the start date of the second subsequent anti-cancer therapy after discontinuation of first subsequent treatment, or death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Arm 1: Dato-DXd","id":"OG000","title":"Dato-DXd"},{"description":"Arm 2: ICC (Capecitabine or Gemcitabine or Eribulin mesylate or Vinorelbine)","id":"OG001","title":"Investigator's Choice of Chemotherapy (ICC)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From randomization to start of second subsequent anti-cancer therapy. Assessments occur at every visit after study treatment has been discontinued. Assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months.","title":"Time to Second Subsequent Therapy (TSST)","type":"SECONDARY","unitOfMeasure":"Months"}